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Whereas	regular	allocation	avoids	unacceptable	mismatches	on	the	donor	organ,	al-
location	to	highly	sensitized	patients	within	the	Eurotransplant	Acceptable	Mismatch	
(AM)	 program	 is	 based	 on	 the	 patient's	HLA	 phenotype	 plus	 acceptable	 antigens.	
These	are	HLA	antigens	to	which	the	patient	never	made	antibodies,	as	determined	
by	extensive	laboratory	testing.	AM	patients	have	superior	long-term	graft	survival	
compared	with	highly	sensitized	patients	in	regular	allocation.	Here,	we	questioned	
whether	the	AM	program	also	results	 in	lower	rejection	rates.	From	the	PROCARE	
cohort,	 consisting	 of	 all	 Dutch	 kidney	 transplants	 in	 1995-2005,	 we	 selected	 de-
ceased	donor	single	transplants	with	a	minimum	of	1	HLA	mismatch	and	determined	
the	cumulative	6-month	rejection	incidence	for	patients	in	AM	or	regular	allocation.	
Additionally,	we	determined	the	effect	of	minimal	matching	criteria	of	1	HLA-B	plus	
1	HLA-DR,	or	2	HLA-DR	antigens	on	rejection	incidence.	AM	patients	showed	sig-
nificantly	lower	rejection	rates	than	highly	immunized	patients	in	regular	allocation,	
comparable	to	nonsensitized	patients,	independent	of	other	risk	factors	for	rejection.	
In	contrast	to	highly	sensitized	patients	in	regular	allocation,	minimal	matching	criteria	
did	not	affect	rejection	rates	in	AM	patients.	Allocation	based	on	acceptable	antigens	
leads	 to	 relatively	 low-risk	 transplants	 for	highly	 sensitized	patients	with	 rejection	
rates	similar	to	those	of	nonimmunized	individuals.
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1  | INTRODUC TION
Sensitization	toward	HLAs	can	occur	through	pregnancy,	blood	trans-
fusion, or transplant.1	When	a	patient	has	formed	antibodies	reactive	
>85%	of	HLA	antigens	present	in	the	donor	population,	this	patient	is	
regarded	as	being	highly	sensitized.2	Highly	sensitized	patients	accrue	
on	the	transplant	waitlist	due	to	the	low	number	of	available	cross-
match-negative	 donors.	 The	 Eurotransplant	 Acceptable	 Mismatch	
program	was	established	almost	30	years	ago	with	the	aim	to	provide	
a	chance	for	highly	sensitized	patients	to	be	transplanted,	which	has	
resulted in >1500 transplants.3	The	program	is	based	on	the	positive	
identification	of	HLA	antigens	to	which	the	patient	has	not	made	any	
antibodies by using extensive laboratory testing.4	 Acceptable	 an-
tigens	are	added	 to	 the	HLA	phenotype	of	 the	patient,	 creating	an	
“extended”	HLA	phenotype,	which	is	used	for	allocation.5	Any	avail-
able	 deceased	 donor	 organ	 that	matches	 this	 extended	 phenotype	
is	mandatorily	allotted	to	the	AM	patient,	resulting	in	 lower	waiting	
times	for	these	highly	sensitized	patients.6,7	Acceptable	antigens	are	
truly	acceptable,	because	no	HLA	match	effect	is	observed	in	patients	
transplanted	 through	 the	AM	program.5,7	 Previously,	 it	was	 shown	
that	the	long-term	graft	survival	of	patients	transplanted	through	the	
AM	program	is	far	superior	to	that	of	their	highly	sensitized	counter-
parts	 transplanted	through	regular	allocation	and	was	even	compa-
rable	to	that	of	nonsensitized	patients.7,8	Because	the	AM	strategy	is	
targeted	at	defining	HLA	antigens	 that	are	 immunologically	accept-
able,	it	is	to	be	expected	that	allocation	based	on	acceptable	antigens	
would	also	result	in	a	lower	rejection	incidence.	Unfortunately,	due	to	
a	lack	of	registration	of	rejection	data	in	the	Eurotransplant	Network	
Information	System,	it	has	not	been	possible	so	far	to	determine	the	
effect	of	the	AM	approach	on	rejection	rates.	The	Dutch	multicenter	
PROCARE	study,	which	includes	clinical	follow-up	of	all	kidney	trans-
plants	 performed	 between	 1995	 and	 2005	 in	 the	 Netherlands,	 al-
lowed	for	the	first	time	the	determination	of	the	effect	of	allocation	
on	rejection	rates	based	on	acceptable	mismatches.
2  | METHODS
2.1 | The AM program
Current	eligibility	criteria	for	inclusion	into	the	AM	program	are	a	cu-
mulative	waiting	time	on	the	Eurotransplant	Kidney	Allocation	System	
(ETKAS)	waitlist	of	≥	2	years	and	a	CDC	PRA	of	>85%	in	either	historic	
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or	current	serum	samples.	In	the	period	of	1995-2005,	acceptable	anti-
gens	were	defined	by	making	use	of	mainly	cellular	assays,	as	described	
elsewhere.5	Briefly,	CDC	assays	were	performed	by	using	patient-spe-
cific	cell	panels	of	lymphocytes	that	had	only	1	HLA	mismatch	with	the	
patient,	in	which	negative	reactions	would	specify	acceptable	antigens.	
Similarly,	a	panel	of	K562	cell	 lines	transfected	with	genes	encoding	
single	HLA	class	I	alleles	were	used	as	targets	in	CDC.	In	the	time	pe-
riod	studied,	solid	phase	assays	were	not	routinely	used.
For	 allocation	 purposes,	HLA	matching	 on	 the	 patient's	 own	
HLA	antigens	and	additional	acceptable	antigens	was	performed	
on	the	split	antigen	level.	Minimal	match	criteria	on	the	identity	of	
either	2	HLA-DR	antigens	or	1	HLA-DR	antigen	with	1	HLA-B	an-
tigen	at	the	split	level	were	adhered	to.	For	patients	with	a	chance	
of	 receiving	 a	 kidney	 through	 the	AM	program	 of	 <0.1%	 (based	
on	 immunological	 grounds),	minimal	HLA	matching	was	 reduced	
to	1	HLA-DR	match	with	 the	patient	on	 the	broad	antigen	 level.	
Furthermore,	whereas	regular	allocation	through	ETKAS	is	based	
on	blood	group	 identity,	AM	patients	 are	 transplanted	based	on	
blood group compatibility.
2.2 | Patients
We	performed	a	post	hoc	analysis	on	the	PROCARE	cohort,	which	
includes	 all	 renal	 transplants	 performed	 in	 the	 Netherlands	 be-
tween	 January	 1995	 and	 December	 2005	 with	 available	 clinical	
follow-up.9	 All	 transplants	 required	 a	 negative	 CDC	 crossmatch	
using	both	peak	and	current	sera.	A	detailed	description	of	the	co-
hort	 has	 been	 published	 previously.10	 Clinical	 data	were	 obtained	
from	 the	Dutch	Organ	Transplant	Registry.	Rejection	was	defined	
as	 the	presence	of	biopsy-proved	acute	 rejection	 (without	 further	
classification)	or	any	treatment	for	acute	rejection	when	no	biopsy	
was	 performed.	 Patients	 transplanted	 through	 regular	 allocation	
(ETKAS)	were	grouped	according	to	the	level	of	sensitization	(0%	to	
5%	peak	PRA:	nonsensitized;	6%	to	85%	peak	PRA:	intermediately	
sensitized;	 and	 >85%	 peak	 PRA:	 highly	 sensitized),	 as	 defined	 by	
CDC	assays.	Patients	included	on	the	AM	waitlist	remained	on	the	
ETKAS	waitlist	 as	well,	 and	 those	who	were	actually	 transplanted	
through	ETKAS	(and	thus	received	an	organ	based	on	the	absence	
of	unacceptable	antigens	only)	are	included	in	the	>85%	PRA	ETKAS	
TA B L E  1  Patient	characteristics
Parameters Categories
ETKAS
AM Total
P
0‐5% PRA 6‐85% PRA >85% PRA
N = 1991 N = 968 N = 121 N = 113 N = 3193
Sex	of	recipient Female 34.3% 48.5% 59.5% 68.1% 1301 <.001
Male 65.7% 51.5% 40.5% 31.9% 1892
Sex	of	donor Female 48.8% 44.6% 47.9% 43.4% 1510 .156
Male 51.2% 55.4% 52.1% 56.6% 1683
Age	of	recipient	(y) ≤50 46.3% 53.9% 64.5% 64.6% 1594 <.001
>50 53.7% 46.1% 35.5% 35.4% 1599
Age	of	donor	(y) ≤50 57.3% 63.1% 61.2% 58.4% 1891 .023
>50 42.7% 36.9% 38.8% 41.6% 1302
Donor type HB 66.5% 73.9% 90.1% 99.1% 2260 <.001
NHB 33.5% 26.1% 9.9% 0.9% 933
Repeat transplant No 93.4% 71.6% 40.5% 46.0% 2654 <.001
Yes 6.6% 28.4% 59.5% 54.0% 539
HLA-A,	-B,	-DR	
mismatch	(broad	
antigen	level)
1, 2, 3 82.5% 81.7% 84.3% 90.3% 2637 .144
4,	5,	6 17.5% 18.3% 15.7% 9.7% 556
Transplant period 1996-2000 45.0% 57.5% 63.6% 42.5% 1577 <.001
2001-2005 55.0% 42.5% 36.4% 57.5% 1616
Initial immunosup-
pressiona 
Pred/cyclo	±	MMF	
±	IL2RA
65.8% 63.2% 64.7% 42.6% 1497 .002
Pred/tacro/MMF	±	
IL2RA
34.2% 36.8% 35.3% 57.4% 828
Initial graft functionb  Direct 64.5% 69.3% 67.3% 79.6% 1991 .002
Delayed 35.5% 30.7% 32.7% 20.4% 997
	AM,	acceptable	mismatch;	cyclo,	cyclosporine;	HB,	heart	beating;	IL2RA,	interleukin-2	receptor	antagonist;	MMF,	mycophenolate	mofetil;	NHB,	
non–heart	beating;	pred,	prednisolone;	tacro,	tacrolimus.
aMissing	values	(n	=	868),	bmissing	values	(n	=	209).	P-values	calculated	with	χ2 test.
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group.	The	study	design	is	schematically	depicted	in	Figure	S1,	and	
patient	characteristics	are	depicted	in	Table	1.	All	patients	provided	
written	 informed	 consent	 for	 use	 of	 their	 clinical	 data.	 The	 study	
protocol	was	approved	by	the	Biobank	Research	Ethics	Committee	
of	the	UMC	Utrecht	(TC	Bio	13-633)	and	performed	in	accordance	
with	the	Declaration	of	Helsinki.
2.3 | Detection and definition of DSAs by 
solid phase
All	available	pretransplant	patient	sera	were	retrospectively	tested	
for	the	presence	of	donor-specific	antibodies	(DSAs)	by	Luminex	sin-
gle	antigen	bead	assays	and	analyzed	 in	context	of	 the	PROCARE	
study as described previously.10
2.4 | Data handling
Groupings	 of	 quantitative	 variables	 were	 based	 on	 the	 following	
strategies:	 transplant	period	was	divided	 into	2	equal	periods,	and	
recipient	 and	 donor	 ages	 of	 50	 years	were	 used	 for	 stratification	
based on previous studies.11	Donor	type	was	defined	as	either	heart	
beating	(HB)	or	non–heart	beating	(NHB).	Initial	immunosuppression	
was	categorized	as	prednisolone/cyclosporine	with	or	without	my-
cophenolate	mofetil	(MMF)	with	or	without	interleukin	(IL)-2	recep-
tor	antagonist	(IL2RA)	versus	prednisolone/tacrolimus/MMF	with	or	
without	IL2RA	based	on	a	previous	study	on	the	complete	PROCARE	
cohort.12	Graft	function	was	categorized	on	direct	or	delayed	func-
tion,	and	HLA	mismatches	were	divided	into	equal	categories.
2.5 | Statistical analysis
The	χ2	test	was	used	to	test	whether	there	was	a	trend	in	the	propor-
tions	with	transplant	characteristics	over	the	4	categories.	Statistical	
significance	was	 determined	 by	 using	 the	 log-rank	 test,	 corrected	
for	 multiple	 comparisons	 (Bonferroni	 method),	 where	 applicable.	
Inclusion	criterion	 for	 the	multivariate	analysis	was	a	univariate	P-
value	of	<.1.	Multivariate	Cox	regression	analysis	was	performed	to	
determine	 independent	 effects	 on	 6-month	 cumulative	 rejection	
incidence. P-values	were	2-tailed,	and	those	<.05	were	considered	
statistically	 significant.	 SPSS	 version	 23	 (IBM,	 Armonk,	 NY)	 and	
GraphPad	 Prism,	 version	 7.04	 (GraphPad	 Software,	 La	 Jolla,	 CA)	
were	used.
3  | RESULTS
3.1 | Allocation based on acceptable mismatches 
results in low rejection rates
To	determine	the	effect	of	allocation	based	on	acceptable	mismatches	
on	the	6-month	cumulative	rejection	incidence,	we	selected	all	de-
ceased	donor	single	renal	transplants	from	1996	to	2005	(in	1996,	
ETKAS	was	initiated13)	with	≥	1	HLA	antigen	mismatch	(HLA-A,	-B,	
or	-DR)	at	the	broad	antigen	level.	We	observed	an	increased	rejec-
tion	incidence	with	increased	sensitization	grade	within	regular	allo-
cation,	with	the	highest	incidence	of	rejection	in	the	highly	sensitized	
patients	transplanted	through	ETKAS	(Figure	1A).	In	contrast,	highly	
sensitized	patients	 transplanted	 through	 the	AM	program	showed	
F I G U R E  1  A,	Comparison	of	6-month	cumulative	rejection	incidence	between	patients	transplanted	through	the	acceptable	mismatch	
(AM)	program	or	through	the	Eurotransplant	Kidney	Allocation	System	(ETKAS).	B,	Comparison	of	5-year	cumulative	rejection	incidence	
between	patients	transplanted	through	the	AM	program	or	through	ETKAS,	for	which	rejection	incidence	was	set	at	zero	on	6	months.	The	
ETKAS	patients	are	subdivided	based	on	their	sensitization	grade:	0%	to	5%	peak	PRA:	nonsensitized;	6%	to	85%	peak	PRA:	intermediately	
sensitized;	and	>85%	peak	PRA:	highly	sensitized.	P	value	calculated	with	log-rank	test	and	corrected	for	multiple	comparisons	(Bonferroni	
method)
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TA B L E  2  Factors	affecting	6-month	cumulative	rejection	incidence	of	highly	sensitized	transplant	recipients	(>85%	PRA)	within	
PROCARE	cohort	(>0	HLA-A,	-B,	-DR	mismatch)
 
Cox regression
Univariate Multivariate Multivariate
HR 95% CI P HR 95% CI P HR 95% CI P
Sex	of	recipient
Female	(ref)             
Male 0.797 0.489 1.300 .364         
Sex	of	donor
Female	(ref)             
Male 0.949 0.599 1.504 .824         
Age	of	recipient	(y)
≤50	(ref)             
>50 0.819 0.502 1.334 .422         
Age	of	donor	(y)
≤50	(ref)             
>50 1.240 0.781 1.969 .362         
Donor type
HB	(ref)             
NHB 1.176 0.429 4.224 .752         
Repeat transplant
No	(ref)             
Yes 0.786 0.497 1.245 .305         
HLA-A,	-B,	-DR	mismatch	(broad	antigen	level)
1,	2,	3	(ref)             
4,	5,	6 1.353 0.712 2.570 .356         
Luminex	defined	DSA
No	(ref)             
HLA	class	I 1.292 0.734 2.276 .374         
HLA	class	II 0.691 0.240 1.991 .493         
HLA	class	I	and	class	II 1.420 0.612 3.296 .415         
Transplant period
1996-2000	(ref)             
2001-2005 0.632 0.394 1.012 .056     0.642 0.387 1.064 .086
Initial immunosuppression
Pred/cyclo	±	MMF	±	IL2RA	
(ref)
            
Pred/tacro/MMF	±	IL2RA 0.581 0.306 1.104 .097 0.665 0.345 1.282 .223     
Initial graft function
Direct	(ref)             
Delayed 1.941 1.190 3.167 .008     1.925 1.163 3.187 .011
Tx	through	AM	program
No	(ref)             
Yes 0.469 0.290 0.758 .002 0.541 0.272 1.073 .079 0.569 0.342 0.945 .029
	AM,	acceptable	mismatch;	CI,	confidence	interval;	cyclo,	cyclosporine;	DSA,	donor-specific	antibody;	HB,	heart	beating;	HR,	hazard	ratio;	IL2RA,	
interleukin-2	receptor	antagonist;	MMF,	mycophenolate	mofetil;	NHB,	non–heart	beating;	pred,	prednisolone;	ref,	reference	value;	tacro,	tacrolimus;	
Tx, transplant.
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similar	rejection	rates	to	those	of	nonsensitized	patients	(P = 1.000)	
and	lower,	although	not	significant,	rejection	rates	than	intermedi-
ately	sensitized	patients	(P = .423).	When	compared	with	their	highly	
sensitized	 counterparts	 transplanted	 through	 regular	 allocation,	
AM	 patients	 experienced	 a	 significantly	 lower	 rejection	 incidence	
(P = .004,	 Figure	1A).	 To	determine	 the	effect	 of	 the	different	 al-
location	 schemes	on	 rejection	 rates	 later	 after	 transplant,	we	also	
analyzed	the	cumulative	rejection	incidence	between	6	months	and	
5	years	and	observed	no	differences	in	this	later	period	(Figure	1B).
We	 next	 performed	 univariate	 Cox	 regression	 analysis	 on	 all	
highly	 sensitized	 patients	 (n	 =	 234)	with	 variables	 that	 potentially	
affect	the	rejection	incidence	(Table	2).	The	variables	of	sex	and	age	
of	 the	 recipient	and	 the	donor,	donor	 type,	 first	 transplant	versus	
repeat	 transplant,	 HLA	 mismatch	 grade,	 transplant	 period,	 initial	
immunosuppression, and presence of single antigen bead–detected 
DSAs	of	 class	 I,	 class	 II,	or	both	class	 I	 and	class	 II	did	not	 signifi-
cantly	affect	the	cumulative	6-month	rejection	incidence.	The	only	
variables	that	affected	the	incidence	of	rejection	were	delayed	graft	
function	 (hazard	ratio	 [HR]	1.94,	95%	confidence	 interval	 [CI]	1.19	
to 3.17; P = .008)	and	 receiving	a	 transplant	 through	 the	AM	pro-
gram	(HR	0.47,	95%	CI	0.29	to	0.76;	P = .002).	The	variables	of	trans-
plant period, initial immunosuppression, initial graft function, and 
transplant	through	the	AM	program	were	selected	for	subsequent	
multivariate	analysis	 to	determine	whether	 the	effect	of	 receiving	
a	transplant	through	the	AM	program	was	 independent.	For	 initial	
immunosuppression,	there	were	missing	values	for	88	patients	(38%)	
due	to	heterogeneous	immunosuppression	protocols	outside	the	2	
main immunosuppression categories. To exclude an interaction be-
tween	 initial	 immunosuppression	 and	 transplant	 through	 the	 AM	
program,	we	first	analyzed	these	variables	in	a	separate	multivariate	
analysis and observed only a minimal effect of initial immunosup-
pression	 on	 the	 variable	 transplant	 through	 the	 AM	 program	 (HR	
changes	from	0.47	to	0.54,	Table	2).	Subsequent	multivariate	anal-
yses on transplant period, initial immunosuppression, initial graft 
function,	and	transplant	through	the	AM	program	showed	that	only	
delayed	graft	function	(HR	1.93,	95%	CI	1.16	to	3.19;	P = .011)	and	
receiving	 a	 transplant	 through	 the	AM	program	 (HR	0.57,	 95%	CI	
0.34	to	0.95;	P = .029)	were	independently	associated	with	6-month	
cumulative	rejection	incidence	(Table	2).
3.2 | Minimal match criteria do not result in lower 
rejection rates in AM patients
It	 has	 previously	 been	 shown	 that	 AM	patients	 transplanted	with	
a	minimal	match	 level	of	2	HLA-DR	antigens	or	of	1	HLA-DR	and	
1	 HLA-B	 antigen	 have	 similar	 graft	 survival	 rates	 compared	 with	
AM	patients	without	this	minimal	level	of	HLA	matching,	raising	the	
possibility	that	the	minimal	match	criteria	for	AM	patients	could	be	
abandoned.3	Importantly,	in	the	current	cohort	we	were	able	to	de-
termine	the	effect	of	the	minimal	match	criteria	on	rejection	rates.	
For	this	analysis,	we	also	included	patients	with	0	HLA	mismatches	
(Figure	S1).	We	found	that	receiving	a	transplant	without	the	afore-
mentioned	minimal	match	 level,	 but	 a	minimum	match	 of	 1	HLA-
DR	on	the	broad	antigen	level,	significantly	increased	the	6-month	
F I G U R E  2  Minimal	match	criteria	do	not	affect	rejection	rates	for	patients	transplanted	through	the	Acceptable	Mismatch	(AM)	program.	
A,	The	6-month	cumulative	rejection	incidence	of	highly	sensitized	patients	transplanted	through	the	Eurotransplant	Kidney	Allocation	
System	(ETKAS)	with	a	minimal	match	level	of	1	HLA-B	and	1	HLA-DR	antigen,	or	2	HLA-DR	antigens	on	the	split	antigen	level	(equivalent	
to	minimal	match	criteria),	or	transplanted	with	1	HLA-DR	match	at	the	broad	antigen	level.	B,	The	6-month	cumulative	rejection	incidence	
of	AM	patients	transplanted	according	to	the	minimal	match	criteria	of	1	HLA-B	and	1	HLA-DR	antigen,	or	2	HLA-DR	antigens	on	the	split	
antigen	level,	or	transplanted	1	HLA-DR	match	at	the	broad	antigen	level
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cumulative	 rejection	 incidence	 in	 patients	 transplanted	 through	
ETKAS	(P < .0001,	Figure	2A),	whereas	no	effect	was	found	in	the	
AM	cohort	(P = .700,	Figure	2B).	The	data	indicate	that	the	minimal	
match	criteria	are	not	beneficial	over	1	HLA-DR	broad	antigen	match	
for	patients	transplanted	through	the	AM	program.
4  | DISCUSSION
It	is	known	that	transplant	to	sensitized	patients	through	regular	al-
location	 is	 associated	 with	 an	 elevated	 risk	 for	 graft	 rejection.14-16 
The	current	study	confirms	these	data,	with	the	cumulative	rejection	
incidence	for	highly	sensitized	patients	transplanted	through	ETKAS	
being	 almost	double	 that	of	 nonsensitized	ETKAS	patients.	 In	 con-
trast,	patients	transplanted	through	the	AM	program	showed	signifi-
cantly	lower	rejection	rates	compared	with	highly	sensitized	patients	
transplanted	through	regular	allocation	and	even	had	similar	rejection	
rates	as	nonsensitized	patients.	On	multivariate	analysis,	receiving	a	
transplant	through	the	AM	program	remained	independently	associ-
ated	with	low	rejection	rates	in	highly	sensitized	patients.	The	occur-
rence	of	rejection	is	known	to	be	a	risk	factor	for	subsequent	inferior	
long-term	graft	 survival.17	 Indeed,	 it	 has	been	described	previously	
that	graft	survival	in	AM	patients	is	far	superior	to	that	in	highly	sen-
sitized	patients	transplanted	through	ETKAS	and	comparable	to	that	
in	nonsensitized	ETKAS	patients.7	Limitations	of	 the	study	are	 that	
it	 does	not	 include	 information	on	whether	 the	 rejections	were	bi-
opsy	proven.	 In	the	PROCARE	database,	rejection	was	defined	as	a	
registered	treatment	for	rejection,	of	which	56.4%	(n	=	456)	were	ac-
companied	by	a	documented	biopsy	specimen	taken	a	day	before	or	
at	the	day	of	initiation	of	antirejection	treatment,	a	percentage	that	
was	evenly	distributed	between	the	different	groups	(P = .122, Table 
S1).	This	is	likely	an	underestimation	due	to	incompleteness	of	the	da-
tabase	for	this	field.	To	obtain	a	more	stringent	selection	on	the	rejec-
tion	events,	we	determine	the	6-month	cumulative	rejection	of	highly	
sensitized	 patients	 (ETKAS	 and	 AM)	without	 any	 rejection	 or	who	
received	a	documented	biopsy-informed	antirejection	treatment	de-
fined	as	described	earlier	and	again	found	that	patients	transplanted	
through	AM	had	a	significantly	 lower	rejection	 incidence	than	their	
highly	sensitized	counterparts	transplanted	through	(Figure	S2).
Second,	we	were	unable	to	further	differentiate	in	type	of	rejec-
tion,	because	a	classification	of	 rejection	 is	not	available	 from	 the	
Dutch	Organ	Transplant	Registry	and	cannot	be	obtained	retrospec-
tively	due	to	the	various	changes	in	BANFF	criteria	over	time.	Finally,	
there	are	no	data	available	regarding	development	of	de	novo	DSAs	
in	the	current	cohort.	With	the	current	study	showing	a	marked	ben-
efit	for	AM	patients,	these	parameters	should	be	included	in	a	con-
secutive	study	on	a	more	recent	cohort.
The	finding	that	allocation	based	on	acceptable	antigens	results	in	
low	rejection	rates	and	excellent	 long-term	graft	survival	can	be	ex-
plained	in	several	ways.	First,	the	absence	of	particular	HLA	antibody	
specificities	is	actively	determined	for	AM	patients	in	both	historic	and	
current	sera,	in	contrast	to	regular	allocation	in	which	unacceptable	an-
tigens	are	determined	and	all	other	antigens	are	presumed	acceptable.	
Second,	there	is	evidence	that	acquired	neonatal	tolerance	explains	a	
proportion of acceptable antigens, because acceptable antigens often 
include	the	noninherited	maternal	antigens.18,19	Third,	either	accept-
able	antigens	could	harbor	a	low	level	of	epitope	mismatches	with	the	
patient	or	the	epitope	mismatches	that	are	present	are	of	low	immu-
nogenicity.20	Preliminary	data	suggest	the	latter,	because	analysis	for	
HLA	class	I	shows	similar	levels	of	epitope	mismatches	for	AM	patients	
and	patients	transplanted	through	regular	allocation,	with	no	effect	of	
the	number	of	epitope	mismatches	on	graft	survival	for	AM	patients	
(Heidt	et	al,	manuscript	in	preparation).
Currently,	 acceptable	 antigens	 for	 HLA-DQA,	 HLA-DPA,	 and	
HLA-DPB	 are	 not	 yet	 accounted	 for	 in	 the	 AM	 program,	 which	
leaves	 the	 possibility	 that	 rejection	 rates	 for	 AM	 patients	 could	
be	 even	 lower	 when	 these	 loci	 are	 also	 taken	 into	 consideration.	
Indeed,	 HLA-DQ	 seems	 to	 be	 the	 dominant	 target	 for	 HLA	 anti-
bodies after transplant.21,22	Future	analyses	 should	show	whether	
extension	of	acceptable	mismatches	to	these	additional	loci	will	in-
deed	 lead	 to	 better	 outcome.	 Such	 analyses	 should	 preferentially	
be	performed	in	the	whole	AM	population,	because	in	the	current	
study	only	transplants	performed	in	the	Netherlands	were	included.	
However,	the	definition	of	acceptable	antigens	is	done	centrally	at	
the	Eurotransplant	Reference	Laboratory,	using	the	same	criteria	for	
all	patients	within	Eurotransplant.	While	confirmation	of	our	results	
within	 the	whole	of	Eurotransplant	 is	 desirable,	we	expect	 similar	
results	to	the	current	study.
In	 addition	 to	 a	 previously	 described	 lack	 of	 effect	 of	 minimal	
match	criteria	on	long-term	graft	survival	in	AM	patients,3	we	show	
a	lack	of	effect	on	rejection	incidence	as	well,	confirming	that	accept-
able	mismatches	are	truly	acceptable.	Together,	these	data	strongly	
support	downscaling	the	minimal	match	criteria	for	AM	patients	to	1	
HLA-DR	broad	antigen	match,	which	can	result	in	around	200	addi-
tional	transplants	to	highly	sensitized	patients	through	the	AM	pro-
gram	each	year.3
Timely	transplant	of	highly	sensitized	patients	 is	of	 the	utmost	
importance	but	should	be	accompanied	by	 low	rejection	rates	and	
long-term	 graft	 survival	 to	 have	 a	 true	 impact	 on	 the	 waitlist	 of	
highly	 sensitized	patients.	We	 show	 that	 transplant	 of	 highly	 sen-
sitized	patients	can	be	achieved	with	comparable	rejection	rates	to	
nonsensitized	patients,	when	acceptable	mismatches	are	used	in	the	
allocation process.
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